Kornimate/medical-research-clean huggingface dataset:
improving immunization rates in transplant candidates through the use of a health information technology tool

Conditions: Transplantation Infection; Vaccination

Summary: vaccine preventable infections are a serious complication following pediatric solid organ transplant. immunizations are a minimally invasive and cost-effective was to reduce these infections. despite the importance of pre-transplant vaccination, the majority of pediatric solid organ transplant recipients are not up-to-date on age-appropriate immunizations at the time of transplant. the goal of this study is to pilot a novel health information technology immunization tool to improve immunization rates in pediatric solid organ transplant candidates.

triads of parents, primary care physicians, and transplant sub-specialists will be enrolled to use a pre-transplant immunization tool while their child awaits transplant. the tool will provide information about vaccines, information about vaccine-preventable infections in the transplant population, a central easily accessible vaccine record, and a communication portal. the tool will also send vaccine reminders when vaccinations are due. the investigators will assess 1) the effectiveness of the tool in improving pre-transplant immunization rates, 2) the acceptability of the tool to users and 3) the feasibility of the tool.

Eligibility criteria:
inclusion criteria: * parent, primary care provider and sub-specialist of a child awaiting heart, liver or kidney transplant exclusion criteria: * non english speaking * no access to a smart phone or computer
continuous glucose monitoring initiation at hospital discharge

Conditions: Type 1 Diabetes; Type2 Diabetes; Hyperglycemia; Hypoglycemia; Hypoglycemia Unawareness

Summary: the purpose of this study is to look at feasibility (the likelihood) of continued use of the freestyle libre 2 continuous glucose monitor (cgm) when started at the time of hospital discharge in patients with poorly controlled diabetes and to look at the effects of cgm use on blood glucose control and quality of life. additional information will be collected to determine the barriers to continuing cgm use after discharge. the investigators will also collect information to see how well blood glucose has been controlled after discharge while utilizing the cgm.

visit/phone call what will happen? (estimated time) \[window\] screening visit (\~45 minutes) review consent form and obtain consent complete questionnaire, obtain diabetes history day of discharge (\~1 hour) complete freestyle libre 2 cgm education attach freestyle libre 2 cgm sensor to arm within 1-3 weeks from discharge phone call (\~30 minutes) questions regarding use of freestyle libre 2 cgm current diabetes regimen adverse events reminder to take freestyle libre 2 cgm sensor prescription to pharmacy to be filled 1 \& 3 month phone call (\~45 minutes) \[+/- 5 days\] questions regarding use of freestyle libre 2 cgm current diabetes regimen complete questionnaire adverse events 6 month phone call (\~15 minutes) \[+/- 10 days\] questions regarding use of freestyle libre 2 cgm barriers to freestyle libre 2 cgm use validated instruments: diabetes self-management questionnaire (dmsq)

Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. have diabetes (type 1 diabetes mellitus, type 2 diabetes mellitus, cystic fibrosis related diabetes mellitus) 3. hemoglobin a1c greater than or equal to 8.0% or history of hypoglycemia unawareness 4. able and willing to sign informed consent form 5. have a valid telephone number 6. willing to purchase freestyle libre 2 cgm sensors out of pocket after discharge from hospital (when insurance coverage isn't available) exclusion criteria: 1. unable to sign informed consent form 2. have altered mental status 3. unable to manage diabetes independently at home 4. have utilized cgm in the past 5. pregnancy 6. new steroid-induced hyperglycemia 7. unwilling to participate in the study 8. have kidney disease requiring hemodialysis 9. taking high doses of vitamin c daily (greater than 500 mg every day)
assessment of metformin as adjuvant therapy in patients with ulcerative colitis

Conditions: Ulcerative Colitis; Inflammatory Bowel Diseases

Summary: brief summary: this is a randomized, controlled study evaluating metformin tablets administered daily for 8 weeks. the purpose of the study is to evaluate the efficacy and safety of metformin in the treatment of mild to moderately active ulcerative colitis. disease activity will be measured using mayo score for ulcerative colitis activity. calculation of the score requires patients to undergo colonoscopy at the start of the study and at week 8.


Eligibility criteria:
inclusion criteria: 1. patients with mild or moderate ulcerative colitis newly diagnosed by colonoscopy and biopsy according to mayo endoscopic scoring of ulcerative colitis. 2. adults (males and/or females) with age range from 18 to 65 years old. 3. patients on treatment with 5-aminosalisylic acid (5-asa) exclusion criteria: 1. patients with severe ulcerative colitis according to mayo endoscopic scoring of ulcerative colitis. 2. treatment with systemic or rectal steroids. 3. treatment with immunosuppressants. 4. previously failed treatment with a sulphasalazine. 5. known hypersensitivity to any of study drugs. 6. hepatic and renal dysfunction. 7. pregnancy and lactation. 8. history of colorectal carcinoma. 9. history of complete or partial colectomy. 10. current or previous treatment with metformin for females with polycystic ovarian syndrome. 11. patients with diabetes mellitus 12. patients with history of lactic acidosis 13. patients with disease states associated with hypoxemia including cardiorespiratory insufficiency 14. positive stool culture for enteric pathogens, positive stool ova and parasite exam.
comparison of laparoscopic hill and laparoscopic nissen anti-reflux procedures

Conditions: Gastroesophageal Reflux; Esophageal Reflux; Gastroesophageal Reflux Disease; GERD

Summary: the purpose of this study is to compare the effects (good and bad) of the laparoscopic hill anti-reflux procedure with the laparoscopic nissen anti-reflux surgical procedure to see whether one is better than the other.

the design is a two-armed prospective single-blinded comparison between the two procedures, performed and randomized independently at the swedish medical center cancer institute in seattle, wa, and at legacy health systems in portland, or, in adult patients with uncomplicated gastroesophageal reflux failing medical management. a standardized operative technique for each procedures will be utilized at both institutions, and will include intraoperative manometrics and intraoperative photographic documentation of the gastroesophageal valve, as well as placement of clips at the ge junction to accurately identify its location post-operatively. to eliminate "expertise" bias, the investigator from each institution will participate in up to 50 of the first of each of the two procedures.

Eligibility criteria:
inclusion criteria: * abnormal levels of gastroesophageal reflux documented by ph monitoring who are failing medical management or are requiring maximal medical therapy for control * \> 18 years of age and \< 75 years of age exclusion criteria: * hiatal hernias measuring \> 7 cm * esophageal body amplitude \< 30 or in two or more segments * \< 40% propagated peristaltic waves * ge junction \> 5 cm above the esophageal hiatus * dense fibrotic esophageal strictures which do not markedly improve with pre-operative medical therapy * body mass index \> 40

Keywords: gerd laparoscopic surgery gastroesophageal reflux
radiation protection with a pelvic lead shield and a radiation protection cap for operators performing coronary angiography or intervention

Conditions: Acute Coronary Syndromes

Summary: radiation protect is a randomized, controlled trial of patients undergoing coronary angiography or pci with or without a pelvic lead shield. interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures. it is hypothesized that routine use of the pelvic lead shield and radiation protection cap during these procedures will reduce the amount of radiation in which the interventional cardiologists get exposed.

patients referred for coronary angiography or pci will be randomized to undergo their procedure with or without the pelvic lead shield and the operator will wear a radiation protection cap. clinical efficacy will be assessed based on the total radiation dose that the interventional cardiologist got exposed to as well as a secondary outcome measuring the total radiation exposure dose per minute.

Eligibility criteria:
inclusion criteria: * patient referred for coronary angiography or percutaneous coronary intervention (pci) exclusion criteria: * age ≤ 18 years * previous inclusion in radiation protect trial

Keywords: radiation protection interventional cardiologist percutaneous coronary intervention (pci) angiography lead shield
comparison of dobutamine and regadenoson stress cardiac magnetic resonance (mr)

Conditions: Coronary Artery Disease; Asthma; Chronic Obstructive Pulmonary Disease (COPD); Angina

Summary: the goal of this research is to determine the utility of regadenoson (lexiscan)for use as an imaging agent with cardiac mr. if found useful, it will help us establish a protocol for regadenoson stress mr perfusion (regadenoson stress test with cardiac mr).the investigators will compare regadenoson with dobutamine so each participant will undergo two studies. a cardiac mr stress test with regadenoson and with dobutamine. the investigators participants will include patients with history of copd and asthma, so it will also help us determine feasibility of regadenoson in these patient's subgroups.


Eligibility criteria:
inclusion criteria: * men and women aged 40 to 85 years with obstructive airway diseases (asthma and copd) and a forced expiratory volume (fev1) \> 0.5. * patients should have a clinical indication to undergo cardiac stress test with dobutamine. exclusion criteria: * those with pacemakers, defibrillators, functioning neural stimulator devices or other implanted electronic devices. * ferromagnetic cerebral aneurism clips or other intraorbital and intracranial metal. * an allergy to gadolinium or other severe drug allergies. * acute myocardial infarction within 3 months. * moderate or severe aortic stenosis or other significant valvular disease; * claustrophobia. * high grade (2o or 3o) av block. * closed angle glaucoma. * participants unable to provide informed consent. * renal dialysis (subjects with moderate-to-severe renal impairment defined as egfr \< 60 ml/min. * a contraindication to receipt of dobutamine. * participants with known coronary artery disease will be included with the exception that patients with left main or narrowings \>50% in the distributions of the left anterior descending, circumflex, and right coronary artery will be excluded.

Keywords: coronary artery disease coronary vessels myocardial ischemia coronary disease ischemic heart disease asthma copd
epidemiology of community - associated extended-spectrum beta-lactamases (esbl) producing escherichia coli

Conditions: Enterobacteriaceae Infections

Summary: the purpose of this study is to review patients with e. coli infections at the university of pittsburgh medical center (upmc) from july 1, 2007 to june 30, 2010 to determine if these infections have arisen in the community rather than in hospitals or nursing homes.

this is chart review at upmc. there is no human interaction.

Eligibility criteria:
inclusion criteria: * all patients with e. coli, klebsiella species and proteus species infections during the time period of the study will be reviewed.

Keywords: isolates infection e coli isolates
ultrasonic visualization of obstructive uropathies in children

Conditions: Obstructive Uropathy

Summary: the purpose of this study was to develop proposals and recommendations for improving the safety of urological examination of children with obstructive uropathy by using doppler ultrasound. based on the results of a comprehensive urological examination of 665 children with congenital ureteral obstruction, a program for scoring the results of ultrasound examination has been developed, which allows using the safest and most informative methods to reliably determine the functional state of the renal parenchyma and the degree of urodynamic disorders in children with obstructive uropathy.

relevance. the prevalence of congenital diseases of the genitourinary system is 0.5-7.5 per 1000 newborns; the high prevalence reflects the medical and social significance of the problem and determines the need to search for highly informative and safe diagnostic methods for the child's body, providing timely treatment, restoration of the somatic and social status of children. purpose. development of proposals and recommendations to improve the safety of urological examination of children with obstructive uropathy. material and methods. the study is based on the analysis of the results of diagnosis and treatment of 655 children with congenital obstruction of the upper urinary tract. the complex of urological examination included clinical, laboratory, morphological, radiological, ultrasound research methods.

Eligibility criteria:
inclusion criteria: * 655 children with congenital obstruction of the upper urinary tract exclusion criteria: * none

Keywords: obstructive uropathy children ultrasound doppler
a study to assess the adverse events and effectiveness of rapid acoustic pulse (rap) device in adult participants for the appearance of cellulite

Conditions: Cellulite

Summary: cellulite is the rippling or dimpling of the skin most commonly located on the thighs and buttocks of women. its appearance and texture are often likened to that of "cottage cheese" or an orange peel. rapid acoustic pulse (rap) is an electrohydraulic (eh) device developed to improve the appearance of cellulite through microscopic disruption of the connection between the skin and underlying tissue leading to a reduction in the severity of dimples and ridges. the purpose of this study is to assess adverse events and effectiveness of rap in adults seeking treatment of cellulite. rap is an fda approved device for the long-term improvement in the appearance of cellulite in the buttocks and thighs. participants 18-50 years of age seeking treatment of cellulite will be enrolled. up to 60 participants will be enrolled in the study at 4 sites in the united states. participants will receive 2 separate cellulite treatment sessions. each treatment session will consist of rap treatment delivered to bilateral thigh and/or buttock areas using the same treatment settings for both sides. the study duration is up to 60 weeks. there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular visits during the study at a clinic. the effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.


Eligibility criteria:
inclusion criteria: * participants seeking treatment of cellulite in the thigh and/or buttock areas. * areas of moderate to severe cellulite on bilateral thigh and/or buttock using the cellulite dimple - at rest scale at baseline with grades of 2 or 3 based on review of photos taken under the same lightening conditions planned for the trial. * participant will not have had invasive or energy-based cellulite (liposuction, subcision, rf, laser, eswt, cryo-lipolysis, muscle stimulation, etc.) treatments in the treatment areas in the prior 12 months. * participant will not have used topical based cellulite treatments for prior 3 months and will not use during the trial * participant will not have used spray-on tanning treatments for 3 months prior to or during the term of the trial. exclusion criteria: * metal or plastic implants (vascular stent, or implants in the hips, knees, etc.) in the treatment areas. * active electronic implants such as pacemakers, defibrillators * history of coagulopathy and/or on anticoagulant medication * skin disorders (skin infections or rashes, psoriasis, etc.) in the treatment areas. * medical disorder that would hinder wound healing or immune response. * any surgical procedure in the treatment areas in the prior 3 months or planned during the duration of the study. * any other condition/disease/situation which, as deemed by the pi, would preclude participant from safely participating in or completing the study visits or that may confound study results.

Keywords: cellulite rapid acoustic pulse rap
a randomized, open-label, losartan therapy on the progression of aortic root dilation in patients with marfan syndrome

Conditions: Marfan Syndrome

Summary: to assess the efficacy of angiotensin ii receptor blocker, losartan, to prevent progressive dilation of aortic root in patients with marfan syndrome.

marfan syndrome (mfs) is a multisystem connective tissue disorder of autosomal dominant inheritance1. the cardinal features are noted in the cardiovascular, ocular, and skeletal system. the most life-threatening complication of mfs is progressive aortic root dilation leading to aortic dissection or rupture. losartan, an angiotensin ii type i receptor (at1) antagonist, is a drug already in clinical use for hypertension and type ii diabetic nephropathy. a recent study showed that losartan prevents aortic root dilation and lung problem in a mouse model of mfs. therefore, the goals of this clinical trial are to examine the efficacy and safety of losartan in patients with marfan syndrome for aortic root dilation prevention.

Eligibility criteria:
inclusion criteria * marfan syndrome with recognized aortic root dilation * patients must be older than one year of age * beta-blocker treatment at least three months * must sign an informed consent form exclusion criteria * prior to aortic root surgery * aortic root dimension more than 5.5cm * aortic surgery within 6 months * diabetes mellitus or liver and renal dysfunction or asthma * pregnancy * intolerance to losartan therapy
a trial investigating safety, tolerability, pk and pd for multiple doses of nnc9204-0530 in male and female subjects being overweight or with obesity

Conditions: Metabolism and Nutrition Disorder; Obesity

Summary: this trial is conducted in the united states of america. the aim of the trial is to investigate safety, tolerability, pk and pd for multiple doses of nnc9204-0530 in male and female subjects being overweight or with obesity


Eligibility criteria:
inclusion criteria: * male or female, age between 18 and 55 years (both inclusive) at the time of signing informed consent * body mass index between 25.0 and 39.9 kg/m\^2 (both inclusive) at screening. exclusion criteria: * haemoglobin a1c (hba1c) equal or above 6.5% * any clinically significant weight change (above or equal to 5% self-reported change) or dieting attempts (e.g. participation in an organized weight reduction program) within the last 90 days prior to screening * any prior obesity surgery or currently present gastrointestinal implant. * abnormal ecg (electrocardiogram) results including 2nd or 3rd degree av-block, prolongation of the qrs complex above 120 ms, or the qtcf interval above 430 ms (males) or above 450 ms (females), or other clinically relevant abnormal results, as judged by the investigator * a history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalaemia, family history of long qt syndrome) * history of pancreatitis (acute or chronic)
aripiprazole once-monthly in patients with schizophrenia

Conditions: Schizophrenia

Summary: to obtain information on the safety, tolerability and effectiveness of aripiprazole once-monthly in a manner consistent with its intended use in everyday clinical practice in patients with schizophrenia who completed study 14724a / nct01795547.


Eligibility criteria:
patients will be recruited among those who complete treatment with aripiprazole in study 14724a / nct01795547. inclusion criteria: * the patient is judged to potentially benefit from 24-week treatment with aripiprazole once-monthly according to the clinical opinion of the investigator. * the patient agrees to protocol-defined use of effective contraception. exclusion criteria: * the patient has been diagnosed with a primary psychiatric disorder other than schizophrenia during study 14724a / nct01795547. * the patient has a clinically significant unstable illness diagnosed during study 14724a / nct01795547. * the patient is at significant risk of harming himself/herself or others according to the investigator's judgement or according to columbia-suicide severity rating scale (c-ssrs). * the patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability or efficacy, or interfere with the conduct or interpretation of the study. * the patient has one or more clinical laboratory test values outside the reference range, based on the blood or urine samples taken during the conduct of study 14724a / nct01795547 that are, in the investigator's opinion, of potential risk to the patient's safety. * the patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason. other inclusion and exclusion criteria may apply.
a prospective study of the effect of treatment of first time traumatic shoulder anterior dislocation by immobilization in external rotation on the incidence of recurrent dislocation

Conditions: Dislocation of the Shoulder

Summary: dislocation of the glenohumeral joint of the shoulder is a common orthopedic clinical problem. the majority of the dislocations are anterior (about 95%) while the rest are posterior and inferior. after reduction of the initial dislocation, the treatment's goal is to prevent recurrent dislocations. in spite of treatment, the recurrence rate is 80-90% in the population aged 18-29. there is an age-related decrease in the recurrence rate, with the only 2-3% for ages 60-70. it has been calculated that 1 in 200 soldiers in the israeli army between the ages of 17 and 33 suffers from recurrent shoulder dislocations \[1\]. the traditional treatment for primary (first-time) shoulder anterior dislocation has been immobilization of the shoulder in internal rotation in a soft dressing called universal shoulder immobilizer (usi) for 3-6 weeks. however, there is a lack of evidence-based information to demonstrate the effectiveness of this treatment. posterior dislocations are immobilized in external rotation. work presented previously in the orthopaedic research society and more recently at the american academy of orthopaedic surgeons suggests that immobilization of the shoulder after reduction of anterior dislocation is best in external rotation and not in internal rotation. mri studies have shown that the labral tear, which is the hallmark of most traumatic anterior dislocations, is best reduced to its anatomical position when the shoulder is immobilized in external and not in internal rotation. preliminary data indicates that immobilization in external rotation of the primary traumatic shoulder dislocations may lower the incidence of reoccurrence. the traditional shoulder immobilizer is a generic bandage produced by several companies. in the current study, the investigators will use a usi distributed by uriel® company (uriel #87), which can be modified to hold the shoulder in external rotation.


Eligibility criteria:
inclusion criteria: * male, age 18-29 * diagnosis of anterior traumatic dislocation of the shoulder * first time dislocation with no history of prior shoulder instability before the present episode * immobilization placed within 48 hours of the acute shoulder dislocation * subject will be in available for 2 years of follow-up * signed informed consent exclusion criteria: * mechanism of injury - motor vehicle accident * associated fracture of tuberosities or glenoid * known collagen disorder * additional conditions that prevent inclusion of patient according to the physician's decision